GRANDPHARMA (00512.HK): Six Products Join Reimbursement and Commercial Insurance Lists

On 15 Nov 2026, GRANDPHARMA (00512.HK) said six products entered China's 2026 reimbursement and commercial insurance lists.

NewTimeSpace News: On 15 November 2026, Grand Pharmaceutical Group Limited (stock code: 512) published a voluntary announcement that six of its products have been included in the 2026 edition of the National Reimbursement Drug List, the 2026 Commercial Health Insurance Innovative Drug List, the first edition of the recommended drug list for commercial health insurance issued by the Insurance Association of China, and the drug table for commercial health insurance cost calculations issued by the China Association of Actuaries.

Its yttrium-90 microsphere injection was selected for the first time for the commercial insurance innovative drug list and the recommended list, and was the only selective internal radiation therapy (SIRT) product added to that list. The product treats patients with unresectable colorectal cancer liver metastases after failure of standard treatment, and is described as the world's first and only SIRT product approved by the US FDA for both unresectable hepatocellular carcinoma and colorectal cancer liver metastases; it has been used more than 150,000 times across over 50 countries and regions in more than 20 years on the market.

Its olopatadine/mometasone nasal spray entered the national reimbursement list for the first time, for moderate-to-severe seasonal allergic rhinitis in adults and children aged six and above and perennial allergic rhinitis in adults and children aged 12 and above. The Company describes it as the only compound nasal spray approved in China for allergic rhinitis in children aged six and above.

Its indacaterol/glycopyrronium inhalation powder, indacaterol/mometasone inhalation powder and eplerenone tablets were renewed on the national list. The first is described as China's first approved triple-combination inhaler for asthma, while eplerenone tablets are a new-generation mineralocorticoid receptor antagonist.

Its carglumic acid dispersible tablets were added to the commercial insurance cost table; the self-developed rare disease drug treats hyperammonaemia caused by N-acetylglutamate synthase deficiency, isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia. Coordinated public and commercial insurance coverage should improve access, ease the treatment burden and speed market penetration, the Company said.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.